Mount Sinai Liver Cancer Program - 14th Anniversary Liver Cancer: Advances in Science and Clinical Management

Friday, December 13, 2019, 8:30 AM - 5:00 PM, Icahn School of Medicine at Mount Sinai, Hatch Auditorium, 1468 Madison Avenue, New York, NY


This conference will assemble multidisciplinary experts on chronic liver diseases, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) from the Mount Sinai Liver Cancer Program and two outstanding invited lecturers. The meeting is intended to provide a summary of the state-of the-art knowledge of the novel advancements reported in 2019 on the pathogenesis and clinical management of liver cancer, including the research conducted in Mount Sinai.

1. Understand the epidemiology and risk factors of liver cancer.
2. Provide adequate clinical indications for the treatment of patients with liver cancer according to the most recent international guidelines.
3. Understand the mechanism of action of novel targeted therapies and immune therapies coming for the management of these diseases.
4. Analyze the prospects of novel therapies (combination therapies and radiation therapy) in the management of liver cancer

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (7.00 hours), Non-Physician Attendance (7.00 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Friday, December 13, 2019

This activity is made possible in part by educational grants from:

Bayer Healthcare

BTG International

Bristol-Meyers Squibb

Celsion Corporation

Eisai

Exelixis

Glycotest

Incyte Corporation